New List of Drugs for Medicare Price Negotiation Include Four Drugs to Treat Cancer

Washington, D.C. - Today, the Trump Administration released the list of 15 drugs for the next round of Medicare price negotiation, including four drugs to treat cancer: Erleada to treat prostate cancer, Kisqali to treat breast cancer, Verzenio to treat breast cancer, and Lenvima to treat thyroid cancer, endometrial cancer, liver cancer, and kidney cancer. According to the Centers for Medicare and Medicaid Services (CMS) approximately 61,000 people with Medicare Part B and D coverage used these four drugs between November 2024 and October 2025. 

The statement below is on behalf of Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), reacting to the announcement.   

“Many cancer patients continue to struggle to access their prescription drugs. We remain supportive of critical steps to ensure prescription drugs are affordable and available for cancer patients. It’s important that the negotiation process ensures that Medicare enrollees benefit directly from the negotiated prices through lower prices but also continued access to their prescriptions. 

“At the same time, it is also imperative that policies to increase affordability also prioritize innovation. This balance is vital to ensuring cancer patients have access to the specific treatments that are best suited to them and their diseases. Cancer includes over 200 different diseases, and our understanding of their biology is constantly evolving and advancing.  

“We recognize that affordability is one component of ensuring access to medically-indicated prescription drugs. We continue to call on CMS to closely monitor the effects on treatment access and affordability for all cancer patients, especially for individuals who are candidates for new, improved therapies."

###